Patent estate

Xeris Pharmaceuticals — Patent Portfolio

1 drug with active patents · 12 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 12/12 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict Xeris Pharmaceuticals' portfolio is moderately strong, with a significant cliff year in 2036 and no revenue at risk in the next 5 years.

Portfolio overview Xeris Pharmaceuticals has a total of 1 drug with patents, out of a total of 1 drugs in their portfolio. The company has 12 active US patents, with an average vulnerability score of 65. Notably, all 12 active patents are vulnerable, with no ironclad patents in the portfolio. The company does not have any biologics with BPCIA exclusivity.

Cliff calendar The company faces a significant cliff year in 2036, with 1 drug losing exclusivity, including Glucagen. This will be the only year with a notable loss of exclusivity in the next decade.

Most exposed drugs The company's most exposed drug is Glucagen, with an earliest active patent expiry date of 2036-02-16, an average vulnerability score of 65, and no annual revenue data available. This drug has 12 patents and is the only drug in the portfolio.

Biologic exclusivity Xeris Pharmaceuticals does not have any biologics in their portfolio, and therefore, there are no biologics with BPCIA 12-year reference product exclusivity.

Strategic implications The company has no revenue at risk in the next 5 years. However, the loss of exclusivity for Glucagen in 2036 will require the company to consider lifecycle management strategies, such as subQ switches, label extensions, or combination filings, to maintain revenue and competitiveness.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2036

Patent estate by drug

Glucagen (GLUCAGON)

Cliff 2036 · 10y
Method of Use 11 Formulation 1
  • US12370241 Vuln 75 2036-02-16
    This patent protects a nasal powder formulation containing glucagon or a glucagon analog for treating severe hypoglycemia.
  • US11590205 Vuln 70 2036-04-22
    This patent protects methods for making stable formulations of a therapeutic glucagon agent using a specific type of solvent and excipient.
  • US11590205 Vuln 70 2036-04-22
    This patent protects methods for making stable formulations of a therapeutic glucagon agent using a specific type of solvent and excipient.
See all 12 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 11 patents
  • Formulation 1 patent

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Xeris Pharmaceuticals's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export